Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment: An Open-Label, Flexible-Dosing, Multicentre Study

By Swift Steven E.  

Clinical Drug Investigation, Vol. 29, Iss. 5, 2009-01 ,pp. : 305-316

Adis International

Access to resources Recommend Favorite

Short-Term Efficacy and Safety of Leflunomide in the Treatment of Active Rheumatoid Arthritis in Everyday Clinical Use: Open-Label, Prospective Study

By Nguyen M.  

Clinical Drug Investigation, Vol. 24, Iss. 2, 2004-01 ,pp. : 103-112

Adis International

Access to resources Recommend Favorite

An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients

By Ersoy Mehmet A.   Noyan Aysin M.   Elbi Hayriye  

Clinical Drug Investigation, Vol. 28, Iss. 2, 2008-01 ,pp. : 113-120

Adis International

Access to resources Recommend Favorite

Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age: Pooled Analysis of Two Open-Label Extension Studies

By Sand Peter K.  

Drugs & Aging, Vol. 29, Iss. 2, 2012-02 ,pp. : 119-131

Adis International

Access to resources Recommend Favorite

Long-term Etanercept Therapy Favors Weight Gain and Ameliorates Cachexia in Rheumatoid Arthritis Patients: Roles of Gut Hormones and Leptin

By  

Current Pharmaceutical Design, Vol. 19, Iss. 10, 2013-03 ,pp. : 1956-1964

Bentham Science Publishers

Access to resources Recommend Favorite